The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise

NCT ID: NCT03073252

Last Updated: 2018-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-01-01

Study Completion Date

2017-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose of this study is to explore the effect of high versus normal egg-based protein meals on acute exercise-induced elevated blood pressure.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is designed to assess BP changes during and post- exercise after consumption of a test breakfast. The design consists of three visits. The first visit will assess each participants aerobic exercise capacity (VO2 max). Visit 2 and 3 will be clinical testing days where the subject will consume either the 13g or 30g protein breakfast in a randomized cross-over manner and perform the exercise intervention. BP changes will be monitored before and after breakfast consumption, during the exercise intervention,

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Pressure Cardiovascular Risk Factor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

subject will consume either the 13g or 30g protein breakfast in a randomized cross-over manner
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors
Care provider will randomize participants and keep the participant, investigator and outcomes assessor blinded to the randomization.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Protein

Consumption of normal protein (NP) meal

Group Type EXPERIMENTAL

Normal Protein

Intervention Type OTHER

Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl

HIgh Protein

Intervention Type OTHER

Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl

High Protein

Consumption of high protein (HP) meal

Group Type EXPERIMENTAL

Normal Protein

Intervention Type OTHER

Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl

HIgh Protein

Intervention Type OTHER

Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Normal Protein

Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl

Intervention Type OTHER

HIgh Protein

Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pre-hypertensive (systolic, 120-139 mm Hg; diastolic, 80-89 mm Hg
* Age ≥ 21
* Body weight \<300 lb (136 kg)
* BMI between 20 and 34.9 kg/m2
* Fasting plasma glucose \<6.1 mmol/L,
* total cholesterol \<6.7 mmol/L
* LDL cholesterol \<4.1 mmol/L
* TG \<4.5 mmol/L
* No pre-existing or history of cardiovascular, renal or liver disease
* Not currently or previously (past 6 mo) consuming a weight-loss diet or other special/non-balanced diets
* No weight loss/gain (±4.5 kg) within the past 6 mo
* No physical impairments preventing properly exercise execution
* No caffeine intake the day of testing

Exclusion Criteria

* Hypertensive
* Body weight ≥ 300 lb
* BMI \<20 or \>35 kg/m2
* Pregnant or planning pregnancy
* Unwilling to consume study foods and beverages
* Fasting plasma glucose ≥6.1 mmol/L
* Total cholesterol ≥6.7 mmol/L
* LDL cholesterol ≥4.1 mmol/L
* TG ≥4.5 mmol/L
* acute illness
* smoking
* diabetic
* pre-existing or history of cardiovascular, renal or liver disease
* currently or previously (past 6 mo) consuming a weight-loss diet or other special/non-balanced diets
* weight loss/gain (±4.5 kg) within the past 6 months
* physical impairments preventing properly exercise execution
* caffeine the day of testing
Minimum Eligible Age

21 Years

Maximum Eligible Age

121 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Purdue University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Wayne Campbell

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Purdue University

West Lafayette, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1607017949

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of NWT-03 on Blood Pressure
NCT02144740 COMPLETED NA